TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38360505

Group type: EXPERIMENTAL
Intervention: Collaborative care model with electronic clinical decision support (CDS)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: High baseline HbA1c≥ 74.9 mmol/mol (9%)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Prompt modification proportions
Number of subjects: 189
Study: 38360588

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (IVT)
Number of subjects: 9973

Group type: EXPERIMENTAL
Intervention: Antiplatelet agents
Number of subjects: 9973

Group type: EXPERIMENTAL
Intervention: Poor functional outcome at 3 months
Number of subjects: 9973

Group type: EXPERIMENTAL
Intervention: Poor functional outcome at 12 months
Number of subjects: 9973

Group type: COMPARATOR
Intervention: Northeastern and central region patients
Number of subjects: 9973
Study: 38360684

Group type: EXPERIMENTAL
Intervention: short fibre DPN with EA
Number of subjects: 48

Group type: COMPARATOR
Intervention: short fibre DPN with sham EA
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: axonal DPN with EA
Number of subjects: 48

Group type: COMPARATOR
Intervention: axonal DPN with sham EA
Number of subjects: 48
Study: 38360686

Group type: EXPERIMENTAL
Intervention: Multi-component pain management pathway facilitated by a pain management coordinator including preoperative education, risk identification, personalized analgesic prescriptions, and continued support up to 8 weeks post-op.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 0
Study: 38360716

Group type: EXPERIMENTAL
Intervention: CHW-led home phototherapy
Number of subjects: 23
Study: 38360739

Group type: EXPERIMENTAL
Intervention: ethinylestradiol/levonorgestrel 30/150 μg
Number of subjects: 180

Group type: COMPARATOR
Intervention: vitamin E 400 IU
Number of subjects: 180
Study: 38360750

Group type: EXPERIMENTAL
Intervention: Integrated health services delivered in a mobile unit with peer navigation for 26 weeks
Number of subjects: 400

Group type: COMPARATOR
Intervention: Peer navigation only for 26 weeks to access the same set of services delivered in community settings
Number of subjects: 400
Study: 38361371

Group type: EXPERIMENTAL
Intervention: Probiotic intervention, details on dosage and duration not specified
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study: 38361924

Group type: EXPERIMENTAL
Intervention: Sickle cell disease participants (StSt)
Number of subjects: 40
Study: 38361940

Group type: EXPERIMENTAL
Intervention: CROSS model
Number of subjects: 255
Study: 38361978

Group type: EXPERIMENTAL
Intervention: Dynamic stimulation pulses
Number of subjects: 13

Group type: COMPARATOR
Intervention: Static stimulation pulses
Number of subjects: 13
Study: 38362052

Group type: EXPERIMENTAL
Intervention: Multidomain intervention through the tablet PC SUPERBRAIN application for 24 weeks, including managing metabolic and vascular risk factors, cognitive training, physical exercise, nutritional guidance, and boosting motivation.
Number of subjects: 300

Group type: COMPARATOR
Intervention: Waiting-list control group receiving no intervention during the study period.
Number of subjects: 300
Study: 38362239

Group type: EXPERIMENTAL
Intervention: Ginge-Cal
Number of subjects: 30

Group type: COMPARATOR
Intervention: Metapex
Number of subjects: 30
Study: 38362338

Group type: EXPERIMENTAL
Intervention: M-atrial natriuretic peptide (single subcutaneous injection)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 38362377

Group type: EXPERIMENTAL
Intervention: Precision-based targeted therapies
Number of subjects: 716

Group type: COMPARATOR
Intervention: Standard neoadjuvant chemotherapy
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: Precision-based targeted therapies in HR+/HER2+ subtype
Number of subjects: 716
Study: 38362466

Group type: EXPERIMENTAL
Intervention: FLASH-RT (dose rate: 220-270 Gy/s)
Number of subjects: 60

Group type: COMPARATOR
Intervention: CONV-RT (dose rate: 0.03-0.06 Gy/sec)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: FLASH-RT
Number of subjects: 60

Group type: COMPARATOR
Intervention: CONV-RT
Number of subjects: 60
Study: 38362600

Group type: EXPERIMENTAL
Intervention: Periodontal therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38362629

Group type: EXPERIMENTAL
Intervention: hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG)
Number of subjects: 28
Study: 38362818

Group type: EXPERIMENTAL
Intervention: Anticoagulation
Number of subjects: 173
Study: 38362837

Group type: EXPERIMENTAL
Intervention: SAR439459 administered intravenously at increasing doses every 2 weeks (Q2W) or every 3 weeks (Q3W) with cemiplimab IV at 3 mg/kg Q2W or 350 mg Q3W.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SAR439459 22.5 mg/kg with cemiplimab 350 mg IV Q3W.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SAR439459 ± cemiplimab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 0
Study: 38362850

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC), followed by surgery and adjuvant chemotherapy (AC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery followed by adjuvant chemotherapy (AC)
Number of subjects: 0
Study: 38362865

Group type: EXPERIMENTAL
Intervention: PRECISE score
Number of subjects: 322
Study: 38362871

Group type: EXPERIMENTAL
Intervention: Back School-based program
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (usual lifestyle)
Number of subjects: 58
Study: 38363272

Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 5050

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5050
Study: 38363314

Group type: EXPERIMENTAL
Intervention: Post-treatment seizures
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Surgical tumor resection
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Mothers having no formal education and lower household monthly income
Number of subjects: 48
Study: 38363446

Group type: EXPERIMENTAL
Intervention: CR with BWSTT (n=16)
Number of subjects: 30

Group type: COMPARATOR
Intervention: CR only (control group, n=14)
Number of subjects: 30
Study: 38363461

Group type: EXPERIMENTAL
Intervention: Pruritus Numeric Rating Scale (Pruritus NRS)
Number of subjects: 21
Study: 38363463

Group type: EXPERIMENTAL
Intervention: Roxadustat treatment (oral medicine for anemia in CKD)
Number of subjects: 444
Study: 38363466

Group type: EXPERIMENTAL
Intervention: Roxadustat treatment (oral), specific dosage not mentioned, duration of treatment evaluated for 12 weeks.
Number of subjects: 2354
Study: 38363467

Group type: EXPERIMENTAL
Intervention: Trofinetide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38363571

Group type: EXPERIMENTAL
Intervention: COVID-19 positive patients receiving chemotherapy (n=110)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: COVID-19 positive patients with severe disease
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: COVID-19 positive patients with SARS-CoV-2 reinfection (n=11)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: COVID-19 positive patients
Number of subjects: 308
Study: 38363589

Group type: EXPERIMENTAL
Intervention: ICory-Circumcision (BuddyCare app and Triumf Health mobile game app)
Number of subjects: 6
Study: 38363591

Group type: EXPERIMENTAL
Intervention: Virtual embodiment training sessions (8 sessions over 4 weeks)
Number of subjects: 24
Study: 38363577

Group type: EXPERIMENTAL
Intervention: Zilebesiran 150 mg, once every 6 months
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Zilebesiran 300 mg, once every 3 months or every 6 months
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Zilebesiran 600 mg, once every 6 months
Number of subjects: 394

Group type: COMPARATOR
Intervention: Placebo, once every 3 months
Number of subjects: 394
Study: 38363727

Group type: EXPERIMENTAL
Intervention: Employment status
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Type of cancer
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Partnership status
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Sex
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Diagnosis category
Number of subjects: 55
Study: 38363733

Group type: EXPERIMENTAL
Intervention: Four-question primary care level screening tool used by Community HIV-care Providers (CHiPs) to identify adolescents at risk of being HIV-positive.
Number of subjects: 42320

Group type: COMPARATOR
Intervention: Universal testing and treatment (UTT) as part of the community-level combination HIV prevention package.
Number of subjects: 42320
Study: 38363772

Group type: EXPERIMENTAL
Intervention: Traditional bread (200 g/d for 8 weeks)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control bread (200 g/d for 8 weeks)
Number of subjects: 31
Study: 38363872

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT)
Number of subjects: 352
Study: 38363950

Group type: EXPERIMENTAL
Intervention: Hip abductor and external rotator strengthening exercises with conventional physical therapy (CPT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Proprioceptive training with conventional physical therapy (CPT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional physical therapy (CPT) alone
Number of subjects: 45
Study: 38363996

Group type: EXPERIMENTAL
Intervention: Exercise Stress Test (EST)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Electrophysiology Study (EPS)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Low-risk findings on EST
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Low-risk EST findings with SPERRI/APERP ≤ 250 ms
Number of subjects: 164
Study: 38364020

Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen (minimum 50 l/min)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Noninvasive bilevel positive pressure ventilation (NIV)
Number of subjects: 60
Study: 38364110

Group type: EXPERIMENTAL
Intervention: Voxelotor
Number of subjects: 8
Study: 38364185

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laser Acupuncture
Number of subjects: 0
Study: 38364191

Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 1050
Study: 38364196

Group type: EXPERIMENTAL
Intervention: Romidepsin plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (Ro-CHOP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP)
Number of subjects: 0
Study: 38364244

Group type: EXPERIMENTAL
Intervention: Transfusion of packed red blood cells (pRBCs)
Number of subjects: 3366
Study: 38364831

Group type: EXPERIMENTAL
Intervention: Atogepant 60 mg once a day
Number of subjects: 313

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study: 38364832

Group type: EXPERIMENTAL
Intervention: Cabozantinib plus atezolizumab
Number of subjects: 432

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Single-agent cabozantinib
Number of subjects: 432
Study: 38365073

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38365118

Group type: EXPERIMENTAL
Intervention: Evenly distributing protein across meals (25-30 g per meal)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Usual intake pattern (most protein at dinner)
Number of subjects: 43
Study: 38365173

Group type: EXPERIMENTAL
Intervention: TAU + WET (Written Exposure Therapy)
Number of subjects: 102
Study: 38365300

Group type: EXPERIMENTAL
Intervention: Intelligent system using deep learning and statistical learning algorithms for detecting congenital anomalies in fetal morphology ultrasound scans.
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Intelligent system during testing phase on previously unseen scans.
Number of subjects: 4000
Study: 38365379

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 78
Study: 38365417

Group type: EXPERIMENTAL
Intervention: Tafenoquine administered to patients with G6PD normal status, aged ≥16 years, not pregnant or breastfeeding.
Number of subjects: 6075

Group type: EXPERIMENTAL
Intervention: G6PD testing before tafenoquine administration.
Number of subjects: 6075

Group type: EXPERIMENTAL
Intervention: Primaquine administered to patients with intermediate or normal G6PD status, aged ≥6 months, not pregnant or breastfeeding >1 month.
Number of subjects: 6075
Study: 38365437

Group type: COMPARATOR
Intervention: Single visit group (SV)
Number of subjects: 39809

Group type: EXPERIMENTAL
Intervention: Return visit group (MV)
Number of subjects: 39809

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 39809

Group type: EXPERIMENTAL
Intervention: Pregnancy
Number of subjects: 39809

Group type: EXPERIMENTAL
Intervention: Presence of comorbidities (e.g., cancer, obesity, organ transplant)
Number of subjects: 39809

Group type: EXPERIMENTAL
Intervention: Current/prior substance use
Number of subjects: 39809

Group type: EXPERIMENTAL
Intervention: Higher temperature or WHO severe disease
Number of subjects: 39809

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 39809

Group type: EXPERIMENTAL
Intervention: Vaccination status (boosted or fully vaccinated)
Number of subjects: 39809
Study: 38365446

Group type: EXPERIMENTAL
Intervention: Extended CPAP
Number of subjects: 36

Group type: COMPARATOR
Intervention: Low-flow nasal cannula (NC)
Number of subjects: 36
Study: 38365502

Group type: EXPERIMENTAL
Intervention: CT-P13 SC (body weight-based dosing every 2 weeks [Q2W]; W6-54)
Number of subjects: 112

Group type: COMPARATOR
Intervention: CT-P13 IV (5 mg/kg Q8W; W6-22) then CT-P13 SC (Q2W; W30-54)
Number of subjects: 112
Study: 38365595

Group type: EXPERIMENTAL
Intervention: Extended point-of-care technology (focused lung ultrasound scan and bedside venous blood analysis) in addition to usual care
Number of subjects: 632

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 632
Study: 38365656

Group type: EXPERIMENTAL
Intervention: COVID-19 pandemic impact on tobacco control programs
Number of subjects: 46
Study: 38365694

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) using 980 nm diode laser, 300 mW, twice weekly for 5 weeks (10 sessions)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Topical 0.1% triamcinolone acetonide three times daily with miconazole oral gel once daily for 4 weeks
Number of subjects: 44
Study: 38365719

Group type: EXPERIMENTAL
Intervention: Habitual sedentary time
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Prolonged sedentary time
Number of subjects: 119
Study: 38365744

Group type: EXPERIMENTAL
Intervention: Combination of glucagon-like peptide 1 receptor analogues and sodium-glucose cotransporter-2 inhibitors
Number of subjects: 60

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 60
Study: 38365756

Group type: EXPERIMENTAL
Intervention: Neoadjuvant vemurafenib, cobimetinib, and atezolizumab (BRAF-mutated)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neoadjuvant cobimetinib and atezolizumab (BRAF-wild-type)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment (both cohorts)
Number of subjects: 30
Study: 38365758

Group type: EXPERIMENTAL
Intervention: Night Shift video game intervention (2 hours within 2 weeks of enrollment and 20 minutes quarterly)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Usual education and training (control)
Number of subjects: 800
Study: 38365814

Group type: EXPERIMENTAL
Intervention: Model-informed precision dosing (MIPD) of vancomycin targeting an AUC24h of 400 to 600 mg × h/L
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care dosing and monitoring according to institutional guidelines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model-informed precision dosing (MIPD) of vancomycin
Number of subjects: 0
Study: 38365820

Group type: EXPERIMENTAL
Intervention: EHR clinician reminder sent to providers prior to scheduled visits
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Pre-visit phone-based educational session conducted by an inreach specialist
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Assessment of provider-patient discussion, screening intentions, and knowledge at baseline and 1-week post-visit
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Assessment of screening referrals and screening completion rates via EHR at 6 months
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Mixed methods and multilevel assessments of patients and providers
Number of subjects: 368
Study: 38365853

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors (SGLT2i) treatment for 12 weeks
Number of subjects: 68
Study: 38365949

Group type: EXPERIMENTAL
Intervention: ganfeborole 5 mg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: ganfeborole 15 mg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: ganfeborole 30 mg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: ganfeborole 1 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: standard of care (Rifafour e-275 or generic alternative)
Number of subjects: 75
Study: 38365951

Group type: EXPERIMENTAL
Intervention: Happy Mother-Healthy Baby program (anxiety-focused cognitive behavioral therapy, six one-on-one sessions)
Number of subjects: 755

Group type: COMPARATOR
Intervention: Enhanced care alone (control group)
Number of subjects: 755
Study: 38365952

Group type: EXPERIMENTAL
Intervention: Lower-dose osocimab
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Higher-dose osocimab
Number of subjects: 704

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 704
Study: 38366021

Group type: EXPERIMENTAL
Intervention: Genomic profiling with large targeted assay (>300 genes, TMB, MSI status)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Molecular profiling on FFPE samples
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Molecular profiling on ctDNA
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: MTB advised molecular-guided treatment options
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Molecular testing and MTB discussion
Number of subjects: 102
Study: 38366225

Group type: EXPERIMENTAL
Intervention: Inhalation of small and ultrasmall graphene oxide nanosheets at a concentration of 200 μg/m3
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 0
Study: 38366267

Group type: EXPERIMENTAL
Intervention: Ambrisentan (2.5/5/7.5 or 10 mg/day)
Number of subjects: 38
Study: 38366324

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 20 μg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Epidural analgesia (fentanyl 100 μg and lidocaine 80 mg)
Number of subjects: 60
Study: 38366572

Group type: EXPERIMENTAL
Intervention: Phenoconversion to Parkinson's disease (PD)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Phenoconversion to dementia with Lewy bodies (DLB)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Phenoconversion to multiple system atrophy (MSA)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Urinary dysfunction
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Sexual dysfunction
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Subtle motor signs
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Trouble swallowing
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Changes in speech
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Deterioration of handwriting
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Difficulty handling utensils
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Younger age of PAF onset
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Preserved olfaction
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Anhidrosis
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Severe urinary problems
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Blunted heart rate increase during tilt-table test
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Annual risk of phenoconversion to CNS synucleinopathy
Number of subjects: 209
Study: 38366591

Group type: EXPERIMENTAL
Intervention: BNT166a (quadrivalent vaccine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BNT166c (trivalent vaccine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BNT166a and BNT166c (both vaccines)
Number of subjects: 0
Study: 38366621

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 665

Group type: COMPARATOR
Intervention: TNFi
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Tofacitinib (in treatment-naïve subpopulation)
Number of subjects: 665

Group type: COMPARATOR
Intervention: TNFi (in treatment-naïve subpopulation)
Number of subjects: 665
Study: 38366672

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 38366675

Group type: EXPERIMENTAL
Intervention: Proximal massage and palm fisting
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard care for PVC
Number of subjects: 72
Study: 38366810

Group type: EXPERIMENTAL
Intervention: Metformin-treated women with PCOS (n=180)
Number of subjects: 365

Group type: COMPARATOR
Intervention: Placebo-treated women with PCOS (n=185)
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Women with PCOS (n=131)
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Pregnancy complications
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Higher body mass index
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Longer duration of labor
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Cesarean section
Number of subjects: 365
Study: 38366824

Group type: EXPERIMENTAL
Intervention: FDG-PET/MRI post 2 cycles (PET2)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: MRI2 response
Number of subjects: 65
Study: 38366886

Group type: EXPERIMENTAL
Intervention: Apatinib plus toripalimab (250 mg apatinib per day plus 240 mg toripalimab on day 1 per 3 weeks)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Physician's choice of chemotherapy (PC)
Number of subjects: 51
Study: 38366909

Group type: EXPERIMENTAL
Intervention: Low-dose group (2 × 10^6 cells)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medium-dose group (20 × 10^6 cells)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose group (80 × 10^6 cells)
Number of subjects: 0
Study: 38367032

Group type: EXPERIMENTAL
Intervention: Low-fat yogurt and butter
Number of subjects: 30

Group type: COMPARATOR
Intervention: Full-fat yogurt
Number of subjects: 30